These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 8975757)

  • 1. Alternatives for a risk assessment on chronic noncancer effects from oral exposure to trichloroethylene.
    Barton HA; Das S
    Regul Toxicol Pharmacol; 1996 Dec; 24(3):269-85. PubMed ID: 8975757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The benchmark dose method--review of available models, and recommendations for application in health risk assessment.
    Filipsson AF; Sand S; Nilsson J; Victorin K
    Crit Rev Toxicol; 2003; 33(5):505-42. PubMed ID: 14594105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trichloroethylene cancer risk: simplified calculation of PBPK-based MCLs for cytotoxic end points.
    Bogen KT; Gold LS
    Regul Toxicol Pharmacol; 1997 Feb; 25(1):26-42. PubMed ID: 9056499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bootstrap estimation of benchmark doses and confidence limits with clustered quantal data.
    Zhu Y; Wang T; Jelsovsky JZ
    Risk Anal; 2007 Apr; 27(2):447-65. PubMed ID: 17511711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health assessment of phosgene: approaches for derivation of reference concentration.
    Gift JS; McGaughy R; Singh DV; Sonawane B
    Regul Toxicol Pharmacol; 2008 Jun; 51(1):98-107. PubMed ID: 18440110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A procedure for developing risk-based reference doses.
    Gaylor DW; Kodell RL
    Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):137-41. PubMed ID: 12051999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints.
    Slob W; Moerbeek M; Rauniomaa E; Piersma AH
    Toxicol Sci; 2005 Mar; 84(1):167-85. PubMed ID: 15483190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calculation of benchmark doses for reproductive and developmental toxicity observed after exposure to isopropanol.
    Allen B; Gentry R; Shipp A; Van Landingham C
    Regul Toxicol Pharmacol; 1998 Aug; 28(1):38-44. PubMed ID: 9784431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-cancer risk assessment for nickel compounds: issues associated with dose-response modeling of inhalation and oral exposures.
    Haber LT; Allen BC; Kimmel CA
    Toxicol Sci; 1998 Jun; 43(2):213-29. PubMed ID: 9710963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procedures for calculating benchmark doses for health risk assessment.
    Gaylor D; Ryan L; Krewski D; Zhu Y
    Regul Toxicol Pharmacol; 1998 Oct; 28(2):150-64. PubMed ID: 9927564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current state of knowledge on the use of the benchmark dose concept in risk assessment.
    Sand S; Victorin K; Filipsson AF
    J Appl Toxicol; 2008 May; 28(4):405-21. PubMed ID: 17879232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment.
    Thomas RS; Clewell HJ; Allen BC; Wesselkamper SC; Wang NC; Lambert JC; Hess-Wilson JK; Zhao QJ; Andersen ME
    Toxicol Sci; 2011 Mar; 120(1):194-205. PubMed ID: 21097997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acrylamide: review of toxicity data and dose-response analyses for cancer and noncancer effects.
    Shipp A; Lawrence G; Gentry R; McDonald T; Bartow H; Bounds J; Macdonald N; Clewell H; Allen B; Van Landingham C
    Crit Rev Toxicol; 2006; 36(6-7):481-608. PubMed ID: 16973444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical risk assessment and uncertainty associated with extrapolation across exposure duration.
    Pohl HR; Chou CH; Ruiz P; Holler JS
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):18-23. PubMed ID: 19944126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final report on the safety assessment of methoxyisopropanol and methoxyisopropyl acetate as used in cosmetics.
    Cosmetic Ingredient Review Expert Panel
    Int J Toxicol; 2008; 27 Suppl 2():25-39. PubMed ID: 18830862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benchmark Dose Workshop: criteria for use of a benchmark dose to estimate a reference dose.
    Barnes DG; Daston GP; Evans JS; Jarabek AM; Kavlock RJ; Kimmel CA; Park C; Spitzer HL
    Regul Toxicol Pharmacol; 1995 Apr; 21(2):296-306. PubMed ID: 7644719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.